VIDEO: Circulating tumor DNA possible biomarker for relapse in DLBCL
Click Here to Manage Email Alerts
Detection of circulating tumor DNA using immunoglobulin-based next generation sequencing within an apheresis stem cell sample predicted relapse after autologous stem cell transplantation among patients with diffuse large B-cell lymphoma.
Identifying circulating tumor DNA (ctDNA) in pre-autologous stem cell transplant (ASCT) plasma appeared to predict relapse as well, according to a presentation from the ASH Annual Meeting and Exposition.
Reid W. Merryman, MD, of Dana-Farber Cancer Institute, and colleagues examined the prognostic value of ctDNA in patients undergoing transplantation to identify novel biomarkers that could effectively detect patients who are likely to do well and those likely to do poorly with transplant.
“The conclusion from this study was that detection of [minimal residual disease] within apheresis stem cell samples was associated with very poor progression-free survival,” Merryman told Healio in a video interview. “I think this gives us an opportunity to investigate alternative treatment strategies for this group of high-risk patients who would do very poorly with autologous stem cell transplantation.
“Our study also showed that plasma-based MRD testing after transplant can identify patients at very high risk of impending relapse and post-transplant plasma MRD testing could serve as a platform for preemptive therapeutic interventions in the setting of a clinical trial,” he continued. “Across the lymphoma field, we’re very excited about ways that we can use emerging data from ctDNA to better guide therapy for our patients.”
Collapse
Merryman RW, et al. Abstract 531. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Click Here to Manage Email Alerts